Evercore ISI analyst Liisa Bayko projects Madrigal's MASH drug sales to exceed $2 billion by 2029, despite competition from anti-obesity medications. The FDA's approval of a MASH drug could boost awareness and patient demand.
The FDA's approval of Rezdiffra exceeded analysts' expectations. The absence of a liver biopsy requirement in Rezdiffra's label is expected to positively impact biotech stocks with exposure to MASH.
Morning Movers Gapping up $Madrigal Pharmaceuticals(MDGL.US)$stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis. $Rivian Automotive(RIVN.US)$stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches. Gapping down $Adobe(ADBE.US)$stock f...
The approval of Rezdiffra is a significant milestone for Madrigal, but the company faces potential competition from cheaper alternatives like GLP-1 weight loss drugs. Despite this, some analysts remain optimistic about Madrigal's prospects, with a price target of $400.
$Madrigal Pharmaceuticals(MDGL.US)$This market is so made up lmao. The price dropped 10% today and the FDA news was leaked before close, but if you check the options, they’re already priced in even with the massive intraday drop. Just shows how fake everything is and how many others are aware of information far before others.
Evercore ISI analyst Liisa Bayko projects Madrigal's MASH drug sales to exceed $2 billion by 2029, despite competition from anti-obesity medications. FDA's approval of a MASH drug could boost condition awareness, leading to more screening and diagnosis.
Madrigal Pharmaceuticals股票讨论区
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x % $Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US)$ $Viking Therapeutics(VKTX.US)$ $Akero Therapeutics(AKRO.US)$ $89bio(ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US)$ $礼来(LLY.US)$ $诺和诺德(NVO.US)$
Gapping up
$Madrigal Pharmaceuticals(MDGL.US)$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US)$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US)$ stock f...
ℹ️ REZDIFFRA (Resmetirom)
⇒ THR-β agonist
⇒ once-daily oral therapy #NASH 💊
⇒ Ph3 MAESTRO-NASH trial
⇒ NDA
⇒ PDUFA: 3/14/24
⇒ Approved under accelerated approval 👏
暂无评论